Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (2) , 185-191
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal periodJournal of Clinical Virology, 2012
- Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre studyBMJ Open, 2011
- Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous systemJournal of Clinical Virology, 2009
- Antivirals for Cytomegalovirus Infection in Neonates and InfantsPediatric Drugs, 2009
- Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2009
- Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategiesJournal of Antimicrobial Chemotherapy, 2009
- Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus DiseaseThe Journal of Infectious Diseases, 2008
- Newborn Hearing Screening — A Silent RevolutionNew England Journal of Medicine, 2006
- Valganciclovir for treatment of congenital cytomegalovirus infectionEuropean Journal of Pediatrics, 2006
- A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisNew England Journal of Medicine, 2002